← Eichor
Condition: Esophageal Squamous Cell Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Esophageal Squamous Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588Ivonescimab Plus Short-Course Hypofractionated Radiotherapy as Second-Line Therapy for Esophageal Squamous Cell Carcinom
Phase 2 · 1 location(s) · Anhui Provincial Hospital · NCT07188103A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizuma
Phase 2/Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07554456Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Phase 2 · 1 location(s) · Dallas VA Medical Center · NCT04018872Study of XB010 in Subjects With Solid Tumors
Phase 1 · 20 location(s) · Exelixis · NCT06545331Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic On
Phase 2 · 2 location(s) · Fudan University · NCT05281003Study on Adjuvant Chemotherapy After Total Two-field Lymph Node Dissection of Thoracic Esophageal Squamous Cell Carcinom
NA · 1 location(s) · Sun Yat-Sen University Cancer Center · NCT04174079Lymphocyte-sparing Thoracic Radiotherapy for Esophageal Squamous Cell Carcinoma
NA · 1 location(s) · Ruijin Hospital · NCT06596954Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy
Phase N/A · 1 location(s) · University of Erlangen-Nürnberg Medical School · NCT04892849Neoadjuvant ChemoRadiotherapy Followed by Immunotherapy and Surgery for Resectable Esophageal Squamous Cell Carcinoma（CR
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT06509568Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
Phase 2 · 1 location(s) · Fujian Medical University Union Hospital · NCT06510660PD-1 Inhibitors Combined With Local Therapy at Different Timings in Oligometastatic ESCC
Phase N/A · 1 location(s) · Fudan University · NCT07697859Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT07177794First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Phase 1 · 10 location(s) · Plexium, Inc. · NCT07284186Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable
Phase N/A · 1 location(s) · Shanghai Zhongshan Hospital · NCT07054086TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
NA · 1 location(s) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC · NCT04481256Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
NA · 2 location(s) · University of California, San Francisco · NCT04221893A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Fujian Cancer Hospital · NCT06463834Immune Indicator Model for Predicting Efficacy of PD-1 Monoclonal Antibody
Phase N/A · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT05392413Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
NA · 1 location(s) · Anhui Provincial Hospital · NCT06602843Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06410651Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophagea
Phase 2 · 1 location(s) · Second Affiliated Hospital of Zunyi Medical University · NCT07559045A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC
Phase 3 · 1 location(s) · National Cancer Center, Japan · NCT04328948A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma
Phase 1/Phase 2 · 1 location(s) · West China Hospital · NCT06753747Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally U
Phase 2 · 1 location(s) · Fuzhou General Hospital · NCT05515315At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers
Phase 2 · 1 location(s) · National University Hospital, Singapore · NCT06422403A Clinical Trial of Ifinatamab Deruxtecan in People With Advanced Esophageal Cancer (MK-3475-06F)
Phase 1/Phase 2 · 22 location(s) · Merck Sharp & Dohme LLC · NCT07405151A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophag
Phase 3 · 1 location(s) · Renmin Hospital of Wuhan University · NCT05919030
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.